CIK 0000943819 · Large accelerated filer
RESMED INC
Sign in to watch- Tickers
- RMD RSMDF
- Exchange
- NYSE, OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 980152841
- Phone
- 8587462400
- Business address
- 9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA, 92123
Securities
- RMD ResMed Inc. Common Stock NYSE
- RSMDF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,744,605
- in 5 filings, $3.7M under 10b5-1 plans
Net −$3,744,605. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-08-18 | Hernandez John Director | Sale | −2,575 | $287.10 | $739K | 4,045 |
| 2025-08-18 | Hernandez John Director | Option exercise · ResMed Common Stock Options | −2,575 | 0 | ||
| 2025-08-15 | Rider Michael J Global General Counsel | Grant or award | +2,941 | 11,427 | ||
| 2025-08-15 | Leong Justin Chief Product Officer | Grant or award | +5,462 | 27,180 | ||
| 2025-08-15 | Sandercock Brett Chief Financial Officer | Grant or award | +5,462 | 88,745 | ||
| 2025-08-15 | Farrell Michael J. Chief Executive Officer | Grant or award | +12,289 | 467,792 | ||
| 2025-08-07 | Farrell Michael J. Chief Executive Officer | Option exercise 10b5-1 | +8,009 | $101.64 | $814K | 463,512 |
| 2025-08-07 | Farrell Michael J. Chief Executive Officer | Sale 10b5-1 | −8,009 | $279.48 | $2.2M | 455,503 |
| 2025-08-07 | Farrell Michael J. Chief Executive Officer | Option exercise · ResMed Common Stock Options 10b5-1 | −8,009 | 24,029 | ||
| 2025-08-01 | Sandercock Brett Chief Financial Officer | Option exercise 10b5-1 | +2,000 | $101.64 | $203K | 86,283 |
| 2025-08-01 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −3,000 | $281.90 | $846K | 83,283 |
| 2025-08-01 | Sandercock Brett Chief Financial Officer | Option exercise · ResMed Common Stock Options 10b5-1 | −2,000 | 6,000 | ||
| 2025-08-01 | Rider Michael J Global General Counsel | Sale 10b5-1 | −50 | $281.90 | $14K | 8,486 |
| 2025-07-07 | Farrell Michael J. Chief Executive Officer | Option exercise 10b5-1 | +8,009 | $101.64 | $814K | 463,512 |
| 2025-07-07 | Farrell Michael J. Chief Executive Officer | Sale 10b5-1 | −8,009 | $256.72 | $2.1M | 455,503 |
| 2025-07-07 | Farrell Michael J. Chief Executive Officer | Option exercise · ResMed Common Stock Options 10b5-1 | −8,009 | 32,038 | ||
| 2025-07-02 | FARRELL PETER C Director | Sale 10b5-1 | −945 | $255.49 | $241K | 68,273 |
| 2025-07-01 | Sandercock Brett Chief Financial Officer | Option exercise 10b5-1 | +1,966 | $101.64 | $200K | 87,249 |
| 2025-07-01 | Sandercock Brett Chief Financial Officer | Option exercise 10b5-1 | +917 | $101.64 | $93K | 88,166 |
| 2025-07-01 | Sandercock Brett Chief Financial Officer | Sale 10b5-1 | −3,883 | $256.99 | $998K | 84,283 |
Page 7 of 18 · 360 trades